Which has higher earnings and valuation, KLRA or AURA?

Aura Biosciences is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is KLRA or AURA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Aura Biosciences N/A -78.12% -64.08%

Does the media favor KLRA or AURA?

In the previous week, Kailera Therapeutics had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Kailera Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Kailera Therapeutics' score of 0.43 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AURA or MOR?

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 192.86%. Given Aura Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aura Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AURA or MOR more profitable?

Aura Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aura Biosciences' return on equity of -78.12% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% MorphoSys -226.79% -694.31% -22.55%

Which has stronger earnings & valuation, TRVI or AURA?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is TRVI or AURA more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Aura Biosciences N/A -78.12% -64.08%

Does the media prefer TRVI or AURA?

In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 3 articles in the media. Trevi Therapeutics' average media sentiment score of 1.35 beat Aura Biosciences' score of 0.83 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMNM or AURA more profitable?

Immunome's return on equity of -51.15% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Aura Biosciences N/A -78.12% -64.08%

Does the media prefer IMNM or AURA?

In the previous week, Immunome had 13 more articles in the media than Aura Biosciences. MarketBeat recorded 16 mentions for Immunome and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Immunome's score of 0.36 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 5 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AURA or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is AURA or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media prefer AURA or SLS?

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat SELLAS Life Sciences Group's score of 0.49 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Aura Biosciences (AURA) Competitors

$7.00 +0.16 (+2.34%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$7.50 +0.50 (+7.13%)

As of 08:33 AM Eastern

Compare

AURA vs. KLRA, MOR, TRVI, IMNM, and SLS

Should you buy Aura Biosciences stock or one of its competitors? MarketBeat compares Aura Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aura Biosciences include Kailera Therapeutics (KLRA), MorphoSys (MOR), Trevi Therapeutics (TRVI), Immunome (IMNM), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

How does Aura Biosciences compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Aura Biosciences (NASDAQ:AURA) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Aura Biosciences is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Kailera Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Aura Biosciences	N/A	-78.12%	-64.08%

96.8% of Aura Biosciences shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Kailera Therapeutics had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Kailera Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Kailera Therapeutics' score of 0.43 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics currently has a consensus target price of $42.75, indicating a potential upside of 114.07%. Aura Biosciences has a consensus target price of $20.50, indicating a potential upside of 192.86%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Kailera Therapeutics beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

How does Aura Biosciences compare to MorphoSys?

Aura Biosciences (NASDAQ:AURA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Aura Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Aura Biosciences has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Aura Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aura Biosciences' return on equity of -78.12% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
MorphoSys	-226.79%	-694.31%	-22.55%

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 192.86%. Given Aura Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aura Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aura Biosciences had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Aura Biosciences and 0 mentions for MorphoSys. Aura Biosciences' average media sentiment score of 0.83 beat MorphoSys' score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aura Biosciences	Positive
MorphoSys	Neutral

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aura Biosciences beats MorphoSys on 12 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trevi Therapeutics' return on equity of -24.53% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 3 articles in the media. Trevi Therapeutics' average media sentiment score of 1.35 beat Aura Biosciences' score of 0.83 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Trevi Therapeutics currently has a consensus target price of $22.67, indicating a potential upside of 37.21%. Aura Biosciences has a consensus target price of $20.50, indicating a potential upside of 192.86%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Trevi Therapeutics beats Aura Biosciences on 10 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Immunome?

Immunome (NASDAQ:IMNM) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Immunome had 13 more articles in the media than Aura Biosciences. MarketBeat recorded 16 mentions for Immunome and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Immunome's score of 0.36 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	5 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome presently has a consensus price target of $33.17, indicating a potential upside of 45.47%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 192.86%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aura Biosciences has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	372.06	-$212.39M	-$2.38	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Immunome has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunome's return on equity of -51.15% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Aura Biosciences	N/A	-78.12%	-64.08%

Summary

Immunome beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Aura Biosciences (NASDAQ:AURA) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Aura Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group's return on equity of -47.12% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 192.86%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 20.76%. Given Aura Biosciences' higher probable upside, equities research analysts clearly believe Aura Biosciences is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat SELLAS Life Sciences Group's score of 0.49 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

SELLAS Life Sciences Group beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$707.16M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-4.02	20.85	27.11	24.26
Price / Sales	N/A	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.24	8.49	10.73	6.29
Net Income	-$106.19M	$23.83M	$3.58B	$330.66M
7 Day Performance	-0.43%	-3.56%	-2.11%	-1.35%
1 Month Performance	9.20%	6.31%	3.27%	-0.64%
1 Year Performance	3.70%	48.30%	26.32%	19.08%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.1887 of 5 stars	$7.00 +2.3%	$20.50 +192.9%	+9.4%	$707.16M	N/A	N/A	50	Analyst Downgrade
KLRA Kailera Therapeutics	4.1789 of 5 stars	$22.24 -4.5%	$42.75 +92.2%	N/A	$2.88B	N/A	N/A	145	Short Interest Increase
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TRVI Trevi Therapeutics	3.482 of 5 stars	$19.50 +8.6%	$22.67 +16.2%	+152.2%	$2.77B	N/A	N/A	20	News Coverage Positive News High Trading Volume
IMNM Immunome	3.2894 of 5 stars	$24.39 +2.1%	$33.17 +36.0%	+163.9%	$2.76B	$6.94M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. KLRA, MOR, TRVI, IMNM, and SLS

How does Aura Biosciences compare to Kailera Therapeutics?

Summary

How does Aura Biosciences compare to MorphoSys?

Summary

How does Aura Biosciences compare to Trevi Therapeutics?

Summary

How does Aura Biosciences compare to Immunome?

Summary

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. KLRA, MOR, TRVI, IMNM, and SLS

How does Aura Biosciences compare to Kailera Therapeutics?

Which has higher earnings and valuation, KLRA or AURA?

Is KLRA or AURA more profitable?

Do insiders & institutionals believe in KLRA or AURA?

Does the media favor KLRA or AURA?

Do analysts rate KLRA or AURA?

Summary

How does Aura Biosciences compare to MorphoSys?

Which has more risk & volatility, AURA or MOR?

Which has better earnings & valuation, AURA or MOR?

Is AURA or MOR more profitable?

Do analysts recommend AURA or MOR?

Does the media prefer AURA or MOR?

Do insiders and institutionals hold more shares of AURA or MOR?

Summary

How does Aura Biosciences compare to Trevi Therapeutics?

Do institutionals & insiders believe in TRVI or AURA?

Is TRVI or AURA more profitable?

Does the media prefer TRVI or AURA?

Which has more volatility and risk, TRVI or AURA?

Which has stronger earnings & valuation, TRVI or AURA?

Do analysts rate TRVI or AURA?

Summary

How does Aura Biosciences compare to Immunome?

Does the media prefer IMNM or AURA?

Do analysts rate IMNM or AURA?

Which has higher valuation & earnings, IMNM or AURA?

Which has more risk & volatility, IMNM or AURA?

Do insiders & institutionals believe in IMNM or AURA?

Is IMNM or AURA more profitable?

Summary

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Which has more volatility & risk, AURA or SLS?

Do institutionals and insiders have more ownership in AURA or SLS?

Is AURA or SLS more profitable?

Do analysts rate AURA or SLS?

Does the media prefer AURA or SLS?

Which has higher earnings & valuation, AURA or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools